ATE313537T1 - Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden - Google Patents
Antagonisten von mcp-1 tätigkeit und deren verwendungsmethodenInfo
- Publication number
- ATE313537T1 ATE313537T1 AT02709746T AT02709746T ATE313537T1 AT E313537 T1 ATE313537 T1 AT E313537T1 AT 02709746 T AT02709746 T AT 02709746T AT 02709746 T AT02709746 T AT 02709746T AT E313537 T1 ATE313537 T1 AT E313537T1
- Authority
- AT
- Austria
- Prior art keywords
- mcp
- antagonists
- activity
- methods
- Prior art date
Links
- 102100021943 C-C motif chemokine 2 Human genes 0.000 title 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27279201P | 2001-03-01 | 2001-03-01 | |
| PCT/US2002/006256 WO2002070509A2 (en) | 2001-03-01 | 2002-02-28 | Antagonists of mcp-1 function and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE313537T1 true ATE313537T1 (de) | 2006-01-15 |
Family
ID=23041292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02709746T ATE313537T1 (de) | 2001-03-01 | 2002-02-28 | Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6809113B2 (enExample) |
| EP (1) | EP1363897B1 (enExample) |
| JP (1) | JP4291576B2 (enExample) |
| KR (1) | KR20040018336A (enExample) |
| CN (1) | CN1259315C (enExample) |
| AR (1) | AR035759A1 (enExample) |
| AT (1) | ATE313537T1 (enExample) |
| BR (1) | BR0207750A (enExample) |
| CA (1) | CA2439849A1 (enExample) |
| DE (1) | DE60208159T2 (enExample) |
| ES (1) | ES2254653T3 (enExample) |
| MX (1) | MXPA03007861A (enExample) |
| TW (1) | TWI245761B (enExample) |
| WO (1) | WO2002070509A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60144284D1 (de) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| US20080187508A1 (en) * | 2004-09-08 | 2008-08-07 | Boys Town National Research Hospital | Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12 |
| NZ560917A (en) | 2005-03-31 | 2011-01-28 | Pfizer Prod Inc | Cyclopentapyridine and tetrahydroquinoline derivatives |
| WO2007066496A1 (en) * | 2005-12-07 | 2007-06-14 | Sumitomo Chemical Company, Limited | Benzoylurea compound and use thereof |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| CA2658719A1 (en) * | 2006-07-24 | 2008-01-31 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation |
| US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| CA2672229A1 (en) * | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| US8356920B2 (en) * | 2007-12-12 | 2013-01-22 | Levine Jonathan E | Lighting device |
| US20100152160A1 (en) * | 2008-12-12 | 2010-06-17 | Khamrai Uttam | Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| EP2522341A1 (en) * | 2011-05-13 | 2012-11-14 | Tragex Pharma | Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| BR122019007990B1 (pt) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| WO2018201091A1 (en) * | 2017-04-27 | 2018-11-01 | Washington University | Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| EP3643711A1 (en) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| ES3066682T3 (en) * | 2021-08-11 | 2026-05-14 | Curadev Pharma Pvt Ltd | Small molecule urea derivatives as sting antagonists |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1250611A (enExample) | 1968-02-03 | 1971-10-20 | ||
| IE32700B1 (en) | 1968-02-03 | 1973-10-31 | Beecham Group Ltd | Penicillins |
| DE2131034A1 (de) * | 1971-06-23 | 1973-01-11 | Hoechst Ag | Acylharnstoffe und verfahren zu ihrer herstellung |
| DE2652004C3 (de) * | 1976-11-15 | 1979-09-13 | Basf Ag, 6700 Ludwigshafen | l-Acyl-2-arylamino-2-imidazoline, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US4163784A (en) | 1978-03-09 | 1979-08-07 | Pfizer Inc. | Heterocyclylcarbonyl derivatives of urea, agents for dissolution of gallstones |
| GB8528234D0 (en) | 1985-11-15 | 1985-12-18 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| JP2650055B2 (ja) | 1988-11-28 | 1997-09-03 | キヤノン株式会社 | 電子写真感光体 |
| FR2672888B1 (fr) | 1991-02-14 | 1994-02-04 | Fabre Medicament Pierre | Nouvelles urees et thiourees, leur preparation et leur application en therapeutique. |
| JP3964478B2 (ja) * | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
| JPH09255572A (ja) | 1996-03-26 | 1997-09-30 | Takeda Chem Ind Ltd | ケモカイン受容体拮抗剤 |
| EP0914319B1 (en) | 1996-05-20 | 2001-11-21 | Teijin Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
| JP2000516210A (ja) | 1996-07-12 | 2000-12-05 | ロイコサイト，インコーポレーテッド | ケモカインレセプターアンタゴニストとその使用方法 |
| AU3633997A (en) * | 1996-07-29 | 1998-02-20 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
| US6184235B1 (en) | 1996-08-14 | 2001-02-06 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as MCP-1 antagonists |
| AU5812498A (en) | 1996-12-20 | 1998-07-17 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
| GB9716656D0 (en) * | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| WO1999040072A1 (de) | 1998-02-03 | 1999-08-12 | Boehringer Ingelheim Pharma Kg | 5-gliedrige benzokondensierte heterocyclen als antithrombotika |
| CN1131217C (zh) * | 1998-07-31 | 2003-12-17 | 日本曹达株式会社 | 苯基吡咯化合物和其制备方法及抗高血脂药 |
| US6316449B1 (en) * | 1999-07-08 | 2001-11-13 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists |
| EP1255743A1 (en) | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa |
| AU2001230537A1 (en) | 2000-02-01 | 2001-08-14 | Daiichi Pharmaceutical Co., Ltd. | Pyridoxazine derivatives |
| AU2001234690A1 (en) | 2000-02-01 | 2001-08-14 | Cor Therapeutics, Inc. | 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa |
-
2002
- 2002-02-25 TW TW091103254A patent/TWI245761B/zh not_active IP Right Cessation
- 2002-02-27 US US10/087,208 patent/US6809113B2/en not_active Expired - Fee Related
- 2002-02-28 MX MXPA03007861A patent/MXPA03007861A/es active IP Right Grant
- 2002-02-28 AT AT02709746T patent/ATE313537T1/de not_active IP Right Cessation
- 2002-02-28 BR BR0207750-7A patent/BR0207750A/pt not_active IP Right Cessation
- 2002-02-28 KR KR10-2003-7011481A patent/KR20040018336A/ko not_active Abandoned
- 2002-02-28 CA CA002439849A patent/CA2439849A1/en not_active Abandoned
- 2002-02-28 EP EP02709746A patent/EP1363897B1/en not_active Expired - Lifetime
- 2002-02-28 DE DE60208159T patent/DE60208159T2/de not_active Expired - Fee Related
- 2002-02-28 WO PCT/US2002/006256 patent/WO2002070509A2/en not_active Ceased
- 2002-02-28 ES ES02709746T patent/ES2254653T3/es not_active Expired - Lifetime
- 2002-02-28 CN CNB028057929A patent/CN1259315C/zh not_active Expired - Fee Related
- 2002-02-28 AR ARP020100728A patent/AR035759A1/es unknown
- 2002-02-28 JP JP2002569829A patent/JP4291576B2/ja not_active Expired - Fee Related
-
2004
- 2004-10-19 US US10/969,440 patent/US7297696B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1259315C (zh) | 2006-06-14 |
| KR20040018336A (ko) | 2004-03-03 |
| WO2002070509A8 (en) | 2003-11-06 |
| WO2002070509A2 (en) | 2002-09-12 |
| HK1060728A1 (en) | 2004-08-20 |
| EP1363897A2 (en) | 2003-11-26 |
| US7297696B2 (en) | 2007-11-20 |
| WO2002070509A3 (en) | 2003-05-30 |
| CN1494539A (zh) | 2004-05-05 |
| MXPA03007861A (es) | 2004-10-15 |
| JP4291576B2 (ja) | 2009-07-08 |
| US20050054668A1 (en) | 2005-03-10 |
| BR0207750A (pt) | 2004-03-23 |
| JP2004527503A (ja) | 2004-09-09 |
| ES2254653T3 (es) | 2006-06-16 |
| CA2439849A1 (en) | 2002-09-12 |
| US6809113B2 (en) | 2004-10-26 |
| EP1363897B1 (en) | 2005-12-21 |
| DE60208159T2 (de) | 2006-08-17 |
| AR035759A1 (es) | 2004-07-07 |
| DE60208159D1 (de) | 2006-01-26 |
| TWI245761B (en) | 2005-12-21 |
| US20030105085A1 (en) | 2003-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60208159D1 (de) | Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden | |
| DE60204548D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| DE60140377D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| DE60222671D1 (de) | Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen | |
| ATE340789T1 (de) | Antagonisten der mcp-1-funktion und verfahren zu deren verwendung | |
| DE60230868D1 (de) | Criptoblockierende antikörper und deren verwendung | |
| DE60239485D1 (de) | Benzamid und heteroarylamid als p2x7-rezeptorantagonisten | |
| DE60227300D1 (de) | Strukturen von anschlusselementen und anzuschliessende komponente | |
| ATE305468T1 (de) | Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten | |
| ID30401A (id) | Turunan-turunan indol dan penggunaannya sebagai antagonis mcp-1 | |
| ATE458717T1 (de) | Beta-amino-alpha-cyanoacrylate und deren verwendung als herbizide | |
| DE60104776D1 (de) | Diphenylharnstoffderivate und deren Verwendung als alpha2/5-HT2c Antagonisten | |
| DE50111690D1 (de) | 2-acyl-indolderivate und deren verwendung als antitumormittel | |
| EP1581622A4 (en) | REMODELING AND GLYCOKON JUGATION OF ERYTHROPOETIN | |
| DE60224194D1 (de) | Arzneizusammensetzungen enthaltend terbinafin und deren verwendung | |
| DE60114413D1 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
| DK1558595T3 (da) | Piperazinyl- og diazapanylbenzamider og -benzthioamider | |
| ATE364575T1 (de) | Zeolithe und deren verwendung | |
| DE60230245D1 (de) | Wabenkonstruktion und deren zusammenbau | |
| DE69903961D1 (de) | Muscarinagonisten und antagonisten | |
| ITMI20021247A1 (it) | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche | |
| DE60302107D1 (de) | Saure Öl-in-Wasser emulgierte Zusammensetzungen und deren Verwendung | |
| DE69915113D1 (de) | 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression | |
| DE60238174D1 (de) | Fluoropolymere und Herstellungs- und Verwendungsverfahren | |
| DE60125374D1 (de) | Bisacrylamid enthaltende dentalmassen und deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1363897 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |